Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 951 - 1,000 out of 12,740

Document Document Title
WO/2013/142124A1
The present application relates to solid state forms, for example, crystalline forms of 2'- C-methyluridine-5 '-(O-phenyl-N-(S)- 1 -(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more s...  
WO/2013/137427A1
Provided is a pyrimidine nucleoside compound represented by general formula (1) [wherein A1 and A2 may be the same as or different from each other and independently represent a hydrogen atom, an alkyloxycarbonyl group which may have a su...  
WO/2013/061105A8
The invention relates to compounds of formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof and processes for preparing them. In formula (I) X is -CH= or -N= or -N(R") -; Y is -N= or -N(R") -; R is an alk...  
WO/2013/135900A1
The present invention provides novel tricyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the tricyclic nucleosides into an oligomeric compound is expected to enhance one or more properties o...  
WO/2013/138236A1
Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and m...  
WO/2013/132489A1
The invention provides particular mono- and dinucleoside 5'-phosphorothioate analogues, more particularly mono- or di- adenosine or uridine 5'-di- or tri- phosphorothioate analogues in which at least one of the bridging oxygen atoms of t...  
WO/2013/128393A1
Disclosed herein is a process for preparing highly pure Citicoline (CDP-Choline) or sodium salt of Citicoline with the aid of dicarboxylic acid or its salts. The process of the present invention results in Citicoline with a purity of mor...  
WO/2013/129667A1
A high-purity acid-form SL containing composition which is characterized by being substantially free from acetic acid. This high-purity acid-form SL containing composition can be prepared, for example, by a process which comprises: (i) a...  
WO/2013/123745A1
The present invention provides an azidothymidine quinoline conjugated compound N-((l-(2-(hydroxymethyl)-5-(5-methyl-2, 4-dioxo-3, 4-dihydro-pyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl)-1H-1, 2, 3-triazol-4-yl) methyl)-6-(4b, 8, 8-trimethyl-...  
WO/2013/068850A3
The present invention provides processes for stereoselectively preparing C-arylglucosides that can be useful as synthetic building block or drugs, including SGLT2 inhibitors.  
WO/2013/122236A1
Provided is a protected nucleotide for elongation that makes it possible to realize a method for producing oligonucleotides by the phosphoramidite process that allows purification to be conducted by liquid-liquid extraction efficiently a...  
WO/2013/121607A1
The present invention addresses the problem of providing a copper catalyst which has higher catalytic activity than conventional copper catalysts, is able to be easily recovered, and can be reused repeatedly. The present invention relate...  
WO/2013/122112A1
Provided is a prodrug of a therapeutically active organic compound having: an amino group, a cyclic amino group or a hydroxyl group in the molecule; and a 2-nitro-1-imidazole propionic acid. In particular, provided is a prodrug in which ...  
WO/2013/112850A1
The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihy droxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for prepa...  
WO/2013/110902A1
The present invention relates to the use of a supramolecular system in order to remove particles from a liquid medium containing same. According to the invention, the supramolecular system includes at least one molecule having a low mole...  
WO/2013/107041A1
A general, facile, and reversible nanocrystal (NCs) phase transfer protocol via ligand exchange using nucleotides and/or nucleosides is provided to generate reversibly water-soluble nanocrystals. This phase transfer strategy can be emplo...  
WO/2013/106344A1
2'-C-methyl nucleosides containing a 5'-monophosphate ester (a cyclic phosphate ester of 1,3-propanediol or 2-oxo-[1,3,2]-dioxaphos-phorinane) Compositions and methods relating to 2'-C-methyl nucleosides containing a 5'-monophosphate est...  
WO/2011/139699A3
The present invention provides 5' modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5'- substituent and an optional 2' substituent...  
WO/2013/061105A3
The invention relates to compounds of formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof and processes for preparing them. In formula (I) X is -CH= or -N= or -N(R") -; Y is -N= or -N(R") -; R is an alk...  
WO/2013/033705A3
A theranostic agent for inhibiting translesion DNA replication comprises natural adenine ribose analog having formula I.  
WO/2012/142523A3
Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2- haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treat...  
WO/2013/096680A1
Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the...  
WO/2013/092447A1
The present invention relates to the use of nucleoside derivatives of formula (I) wherein the symbols are as the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.  
WO/2013/092481A1
The present disclosure relates to compounds of Formula (I): Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of using the compounds of Formula (I) and/or compositions comprising the compounds of...  
WO/2013/096679A1
Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are meth...  
WO/2013/090550A1
Compounds of formula (I) as shown in the disclosure, in which X, Y, and Z are defined herein. Also disclosed are pharmaceutical compositions and therapeutical methods related to these compounds.  
WO/2013/084165A1
The invention provides compounds of the formula:(I) which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.  
WO/2013/078517A1
A method for isolating aragonite and organic constituents from nacre-coated shell or pearl comprising the steps: exposing the nacreous layer of nacre-coated shell or pearl to an ionic liquid; and isolating the aragonite and organic const...  
WO/2012/140596A8
The present invention provides a compound of formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ...  
WO/2011/123621A3
The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2):Formula (1) and Formula (2). Another aspect of the invention relates to a method of inhibiting the expression...  
WO/2013/067666A1
Disclosed is a method for preparing zidovudine (B). The method comprises the following steps: 1) 2'-halothymidine (A) is used as the raw material to obtain a compound of formula (I) by protecting the hydroxyl group thereof in the 5'-posi...  
WO/2013/067664A1
The present invention relates to a method for preparing zidovudine (B). The method comprises the following steps: 1) 2'-halothymidine (A) is used as the raw material to obtain a compound of formula (I) by protecting the hydroxyl group th...  
WO/2011/139695A3
Provided herein are modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom. More particularly, modified 5' diphosphate nucleosides are provided that can be further modified at the 2' and 5' positions. In some emb...  
WO/2013/067669A1
Provided is a method for preparing zidovudine (C). The method comprises the following steps: 1) 2'-halothymidine (B) is used as the raw material to obtain a compound of formula (I) by protecting the hydroxyl group thereof in the 5'-posit...  
WO/2011/005860A3
The present invention provides nucleosides and oligonucleotides comprising a 5' phosphate mimics of formula (IVc) or (Vc). One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleot...  
WO/2012/177701A3
The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein theD02S derivatives having the following structure: wherein R1', R2' are each independe...  
WO/2011/139702A3
The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporatio...  
WO/2013/061105A2
The invention relates to compounds of formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof and processes for preparing them. In formula (I) X is -CH= or -N= or -N(R") -; Y is -N= or -N(R") -; R is an alk...  
WO/2013/036846A3
The present invention provides hydrophobic prodrugs of nucleic acid bases, nucleosides, and nucleotides. The compounds of the invention have a structure according to Formula I. Methods for the hypomethylation of oligonucleotides, treatme...  
WO/2010/084115A3
Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; as defined herein, are described for use in the prevention and/or treatment of HCV infections. Novel compounds of the formula (I) and pharmaceutical form...  
WO/2013/056046A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2013/055252A1
The invention relates to the field of molecular biology, virology and medicine and concerns novel biologically active compounds, more specifically salts of carbamoyl phosphonic acid esters of the general formula given in the description....  
WO/2013/047567A1
Flavin adenine dinucleotide or a salt thereof significantly curbs the decline in viable cell count of corneal epithelial cells induced by ultraviolet radiation, and thus can act as an inhibitor of corneal epithelial cell death induced by...  
WO/2013/044811A1
The present invention relates to the field of medical technology, and in particular relates to a kind of gemcitabine amide derivative with a novel structure. The new compounds of the present invention are very active with regard to many ...  
WO/2013/040257A1
The present invention relates generally to 3'-OH unblocked nucleotides and nucleosides labeled and unlabeled with 5-methoxy-substituted nitrobenzyl-based photocleavable terminating groups for use in methods and systems related to DNA and...  
WO/2013/039855A1
Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered eith...  
WO/2013/036868A1
Synthesis and uses of conformationally restricted nucleomonomers (CRN) to prepare nucleic acid compounds. Methods for preparing nucleomonomers for nucleic acid compounds in high yields and in multi-gram scale for therapeutic modalities u...  
WO/2013/036846A2
The present invention provides hydrophobic prodrugs of nucleic acid bases, nucleosides, and nucleotides. The compounds of the invention have a structure according to Formula I. Methods for the hypomethylation of oligonucleotides, treatme...  
WO/2013/033705A2
A theranostic agent for inhibiting translesion DNA replication comprises natural adenine ribose analog having formula I.  
WO/2013/026424A1
A method for the' preparation of 2-[4-[(methylamino)carbonyl]-1-H-pyrazol-1- yl]adenosine monohydrate of formula I by reaction of 2-(4-methoxycarbonylpyrazol-1-yl) adenosine of formula III with a solution of methylamine in a non-aqueous ...  

Matches 951 - 1,000 out of 12,740